9 results on '"Roostaei, Tina"'
Search Results
2. A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility
- Author
-
Sorosina, Melissa, Barizzone, Nadia, Clarelli, Ferdinando, Anand, Santosh, Lupoli, Sara, Salvi, Erika, Mangano, Eleonora, Bordoni, Roberta, Roostaei, Tina, Mascia, Elisabetta, Zuccalà, Miriam, Vecchio, Domizia, Cavalla, Paola, Santoro, Silvia, Ferrè, Laura, Zollo, Alen, Barlassina, Cristina, Cusi, Daniele, Martinelli, Vittorio, Comi, Giancarlo, Leone, Maurizio, Filippi, Massimo, Patsopoulos, Nikolaos A, De Jager, Philip L, De Bellis, Gianluca, Esposito, Federica, D'Alfonso, Sandra, Martinelli Boneschi, Filippo, Paolo Ragonese, Sorosina, Melissa, Barizzone, Nadia, Clarelli, Ferdinando, Anand, Santosh, Lupoli, Sara, Salvi, Erika, Mangano, Eleonora, Bordoni, Roberta, Roostaei, Tina, Mascia, Elisabetta, Zuccalà, Miriam, Vecchio, Domizia, Cavalla, Paola, Santoro, Silvia, Ferrè, Laura, Zollo, Alen, Barlassina, Cristina, Cusi, Daniele, Martinelli, Vittorio, Comi, Giancarlo, Leone, Maurizio, Filippi, Massimo, Patsopoulos, Nikolaos A, De Jager, Philip L, De Bellis, Gianluca, Esposito, Federica, D'Alfonso, Sandra, Martinelli Boneschi, Filippo, and Paolo Ragonese
- Subjects
Neurology ,Genetics, Genome-wide association study, Multiple sclerosis, Susceptibility, TBKBP1 ,Neurology (clinical) - Abstract
Background Over 200 genetic loci have been associated with multiple sclerosis (MS) explaining ~ 50% of its heritability, suggesting that additional mechanisms may account for the “missing heritability” phenomenon. Objective To analyze a large cohort of Italian individuals to identify markers associated with MS with potential functional impact in the disease. Methods We studied 2571 MS and 3234 healthy controls (HC) of continental Italian origin. Discovery phase included a genome wide association study (1727 MS, 2258 HC), with SNPs selected according to their association in the Italian cohort only or in a meta-analysis of signals with a cohort of European ancestry (4088 MS, 7144 HC). Top associated loci were then tested in two Italian cohorts through array-based genotyping (903 MS, 884 HC) and pool-based target sequencing (588 MS, 408 HC). Finally, functional prioritization through conditional eQTL and mQTL has been performed. Results Top associated signals overlap with already known MS loci on chromosomes 3 and 17. Three SNPs (rs4267364, rs8070463, rs67919208), all involved in the regulation of TBKBP1, were prioritized to be functionally relevant. Conclusions No evidence of novel signal of association with MS specific for the Italian continental population has been found; nevertheless, two MS loci seems to play a relevant role, raising the interest to further investigations for TBKBP1 gene.
- Published
- 2022
3. A structured evaluation of cryopreservation in generating single-cell transcriptomes from cerebrospinal fluid
- Author
-
Touil, Hanane, primary, Roostaei, Tina, additional, Calini, Daniela, additional, Diaconu, Claudiu, additional, Epstein, Samantha, additional, Raposo, Catarina, additional, Onomichi, Kaho, additional, Thakur, Kiran T., additional, Craveiro, Licinio, additional, Callegari, Ilaria, additional, Bryois, Julien, additional, Riley, Claire S., additional, Menon, Vilas, additional, Derfuss, Tobias, additional, De Jager, Philip L., additional, and Malhotra, Dheeraj, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Neuropathological correlates and genetic architecture of microglial activation in elderly human brain
- Author
-
Felsky, Daniel, Roostaei, Tina, Nho, Kwangsik, Risacher, Shannon L., Bradshaw, Elizabeth M., Petyuk, Vlad, Schneider, Julie A., Saykin, Andrew, Bennett, David A., and De Jager, Philip L.
- Published
- 2019
- Full Text
- View/download PDF
5. Classification algorithms with multi-modal data fusion could accurately distinguish neuromyelitis optica from multiple sclerosis
- Author
-
Eshaghi, Arman, primary, Riyahi-Alam, Sadjad, additional, Saeedi, Roghayyeh, additional, Roostaei, Tina, additional, Nazeri, Arash, additional, Aghsaei, Aida, additional, Doosti, Rozita, additional, Ganjgahi, Habib, additional, Bodini, Benedetta, additional, Shakourirad, Ali, additional, Pakravan, Manijeh, additional, Ghana'ati, Hossein, additional, Firouznia, Kavous, additional, Zarei, Mojtaba, additional, Azimi, Amir Reza, additional, and Sahraian, Mohammad Ali, additional
- Published
- 2015
- Full Text
- View/download PDF
6. Effect of Vitamin A Supplementation on fatigue and depression in Multiple Sclerosis patients: A Double-Blind Placebo-Controlled Clinical Trial.
- Author
-
Bitarafan, Sama, Saboor-Yaraghi, Aliakbar, Sahraian, Mohammad-Ali, Soltani, Danesh, Nafissi, Shahriar, Togha, Mansoureh, Moghadam, Nahid Beladi, Roostaei, Tina, Honarvar, Niyaz Mohammadzadeh, Harirchian, Mohammad-Hossein, Beladi Moghadam, Nahid, and Mohammadzadeh Honarvar, Niyaz
- Subjects
MULTIPLE sclerosis ,VITAMIN A ,FATIGUE (Physiology) ,MENTAL depression ,CLINICAL trials ,MEDICAL research ,PATIENTS ,ANTIDEPRESSANTS ,DIAGNOSIS of mental depression ,MULTIPLE sclerosis diagnosis ,THERAPEUTIC use of vitamin A ,COMPARATIVE studies ,DIETARY supplements ,FUNCTIONAL assessment ,RESEARCH methodology ,MEDICAL cooperation ,PSYCHOLOGICAL tests ,RESEARCH ,TIME ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment ,DISEASE complications ,DIAGNOSIS - Abstract
Decreasing the population and activation of inflammatory T helper cells in multiple sclerosis (MS) patients using vitamin A derivatives (retinoic acids) has been well documented. The present study determined the effect of vitamin A supplementation on psychiatric signs in MS patients. The subjects were 101 relapsing-remitting MS patients enrolled in a placebo-controlled randomized clinical trial. The treatment group was administered 25000 IU/d retinyl palmitate (RP) for 6 months followed by 10000 IU/d RP for another 6 months. The results for baseline characteristics, modified fatigue impact scale and Beck Depression Inventory-II were recorded at the beginning and end of the one-year study. The non-normal distribution data was compared between groups using a nonparametric test and normal distribution data was analyzed using a parametric test. (ClinicalTrials.gov Identifiers: NCT01417273). The results showed significant improvement in the treatment group for fatigue (p=0.004) and depression (p=0.01). Vitamin A supplementation helped during interferon therapy in the treatment process and improved psychiatric outcomes for anti-inflammatory mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2016
7. Impact of Melatonin on Motor, Cognitive and Neuroimaging Indices in Patients with Multiple Sclerosis.
- Author
-
Roostaei, Tina, Sahraian, Mohammad Ali, Hajeaghaee, Sara, Gholipour, Taha, Togha, Mansoureh, Siroos, Bahaadin, Mansouri, Sepideh, Mohammadshirazi, Zahra, Alasti, Maryam Aghazadeh, Harirchian, Mohammad Hossein, and Aghazadeh Alasti, Maryam
- Subjects
- *
INFLAMMATION , *MELATONIN , *MOTOR ability , *COGNITIVE ability , *BRAIN imaging , *IMMUNOLOGICAL adjuvants , *PLACEBOS , *BRAIN , *COGNITION , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *MULTIPLE sclerosis , *NEURORADIOLOGY , *RESEARCH , *STATISTICAL sampling , *EVALUATION research , *RANDOMIZED controlled trials , *BLIND experiment , *PHARMACODYNAMICS - Abstract
A series of preclinical and clinical studies have shown the immunomodulatory effect of melatonin, especially in the state of chronic inflammation. A double-blind, randomized, parallel-group, placebo-controlled clinical trial was designed to study the tolerability and efficacy of supplemental therapy with melatonin (3 mg/day) in comparison to placebo in relapsing-remitting MS (RRMS) patients receiving once weekly interferon beta. Patients were followed up for 12 months. Primary outcomes consisted of the number of relapses, change in Extended Disability Status Scale (EDSS), and the number and volume of new T2 and gadolinium-enhancing brain lesions. Secondary outcomes included change in performance on Multiple Sclerosis Functional Composite (MSFC) as well as change in fatigue and depression. The outcomes were evaluated every three months. Twenty-six patients (13 in each group) were recruited in the study. All participants, except for one patient in the placebo group, completed the study. No patient reported serious adverse events. There was no significant difference either in primary or secondary outcomes between melatonin and placebo arm. However, a trend for beneficial effect was observed for melatonin on change in MSFC performance and the cognitive subscore of the Modified Fatigue Impact Scale (p=0.05 and 0.006, respectively, not corrected for multiple comparisons). We found no significant effect for treatment with melatonin on measures of clinical and functional disability and development of brain lesions in our small sample-size study. Studies with higher statistical power and longer follow up are needed to further evaluate the potential immunomodulatory effect of melatonin in RRMS treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2015
8. Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer’s disease
- Author
-
Roostaei, Tina, Nazeri, Arash, Felsky, Daniel, De Jager, Philip L., Schneider, Julie A., Pollock, Bruce G., Bennett, David A., and Voineskos, Aristotle N.
- Abstract
The lack of strong association between brain beta-amyloid deposition and cognitive impairment has been a challenge for the Alzheimer’s disease (AD) field. Although beta-amyloid is necessary for the pathologic diagnosis of AD, it is not sufficient to make the pathologic diagnosis or cause dementia. We sought to identify the genetic modifiers of the relation between cortical beta-amyloid burden (measured using [18F]Florbetapir-PET) and cognitive dysfunction (measured using ADAS-cog) by conducting a genome-wide interaction study on baseline data from participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) phases GO/2 (n=678). Near genome-wide significant interaction effect was observed for rs73069071 within the IAPP (amylin) and SLCO1A2 genes (P=6.2×10−8). Congruent results were found using data from participants followed up from ADNI-1 (Pone-tailed=0.028, n=165). Meta-analysis across ADNI-GO/2 and ADNI-1 revealed a genome-wide significant interaction effect (P=1.1×10−8). Our results were further supported by similar interaction effects on temporal lobe cortical thickness (whole-brain voxelwise analysis: family-wise error corrected P=0.013) and longitudinal changes in ADAS-cog score and left middle temporal thickness and amygdalar volume (Pone-tailed=0.026, 0.019, and 0.003, respectively). Using postmortem beta-amyloid immunohistochemistry data from 243 AD participants in the Religious Orders Study and Memory and Aging Project, we also observed similar rs73069071-by-beta-amyloid deposition interaction effect on global cognitive function (Pone-tailed=0.005). Our findings provide insight into the complexity of the relationship between beta-amyloid burden and AD-related cognitive impairment. Although functional studies are required to elucidate the role of rs73069071 in AD pathophysiology, our results support the recently growing evidence on the role of amylin in AD.
- Published
- 2016
- Full Text
- View/download PDF
9. Impact of Vitamin A Supplementation on Disease Progression in Patients with Multiple Sclerosis.
- Author
-
Bitarafan, Sama, Saboor-Yaraghi, Aliakbar, Sahraian, Mohammad-Ali, Nafissi, Shahriar, Togha, Mansoureh, BeladiMoghadam, Nahid, Roostaei, Tina, Siassi, Fereydoun, Eshraghian, Mohammad-Reza, Gha-naati, Hossein, Jafarirad, Sima, Rafiei, Behrouz, and Harirchian, Mohammad-Hossein
- Abstract
Background: Many studies have shown that active vitamin A derivatives suppress the formation of pathogenic T cells in multiple sclerosis (MS) patients. The aim of the present study is to determine the impact of vitamin A on disease progression in MS patients. Methods: A total of 101 relapsing-remitting MS (RRMS) patients were enrolled in a 1-yr placebo-controlled randomized clinical trial. The treated group received 25000IU/d retinyl palmitate for six months followed by 1 OOOOIU/d retinyl palmitate for another six months. The results of the expanded disability status scale (EDSS) and multiple sclerosis functional composite (MSFC) were recorded at the beginning and the end of the study. The relapse rate was recorded during the intervention. Patients underwent baseline and follow-up brain MRIs. Results: The results showed 'Mean ± SD' of MSFC changes in the treated group was (-0.14 ± 0.20) and in the placebo group was (-0.31 ±0.19). MSFC was improved significantly (p< 0.001) in the treatment group. There were no significant differences between the 'Mean ± SD' of EDSS changes in thet-reated (0.07 ± 0.23) and the placebo (0.08 ± 0.23) groups (p = 0.73). There were also no significant differences between the 'Mean ± SD' of annualized relapse rate in the treated group (-0.36 ± 0.56) and placebo (-0.53 ± 0.55) groups (p = 0.20). The 'Mean ± SD' of enhanced lesions in the treatment (0.4 ± 1.0) and in the placebo (0.2 ± 0.6) groups were not significantly different (p = 0.26). Volume of T2 hyperintense lesions 'Mean ± SD' was not significantly different between treatment (45 ± 137) and placebo (23 ± 112) groups after intervention (p = 0.23). Conclusion: Vitamin A improved total MSFC score in RRMS patients, but it did not change EDSS, relapse rate and brain active lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.